Elena S. Fatenkova

Elena S. Fatenkova

Auto-generated profile, based on publicly available information

Elena S. Fatenkova

Samara State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
IKIgor V. Kurtov
Igor V. Kurtov
AOAlexey M. Osadchuk
Alexey M. Osadchuk
EFElena S. Fatenkova
Elena S. Fatenkova
AKAlexandra I. Kurtova
Alexandra I. Kurtova
IDIgor L. Davydkin
Igor L. Davydkin
The article shows the possible use of sulodexidi in a patient with primary infertility of unknown origin associated with an excess of the plasminogen activator type 1 inhibitor. This method illustrates the possibility of pregnancy when taking sulodexidi at the stage of pregravidar preparation in a woman with hypofibrinolysis.

26 December 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
IDI. L. Davydkin
I. L. Davydkin
EME. V. Mordvinova
E. V. Mordvinova
ТКТ. П. Кузьмина
Т. П. Кузьмина
KNK. V. Naumova
K. V. Naumova
EFE. S. Fatenkova
E. S. Fatenkova
The article is devoted to the modern understanding of endothelial dysfunction development, the role of hyperhomocysteinemia, and, as a consequence, hypertension in patients with multiple myeloma receiving multiagent chemotherapy. Considering that the potential of a standard examination does not allow identifying subclinical endothelial dysfunction, using specific techniques is necessary, in particular, to determine the homocysteine level to monitor the endothelial function.The aim of this review was to summarize the current understanding of hypertension etiology and prospects for detecting early, subclinical endothelial changes, including in patients with multiple myeloma.Assessment of endothelial dysfunction can be useful for detecting precisely the subclinical cardiovascular disease in order to stratify the risk of developing cardiovascular events in patients receiving multiagent chemotherapy.

27 September 2020 in Тромбоз, гемостаз и реология
Verified
Journal Article
Closed access
ИКИгорь Валентинович Куртов
Игорь Валентинович Куртов
ЕФЕ.с. Фатенкова
Е.с. Фатенкова
НЮН.а. Юдина
Н.а. Юдина
АОА.м. Осадчук
А.м. Осадчук
ИДИ.л. Давыдкин
И.л. Давыдкин
Болезнь Виллебранда (БВ) может представлять определенные трудности у рожениц с данной патологией. Приведены 2 клинических примера использования у женщин с БВ фактора VIII свертывания крови с фактором Виллебранда, показана эффективность и безопасность их применения. У одной пациентки было также показано использование фактора свертывания крови VIII с фактором Виллебранда во время экстракорпорального оплодотворения. Von Willebrand disease presents a certain hemostatic problem among parturients. This article shows the effectiveness and safety of using coagulation factor VIII with von Willebrand factor for the prevention of bleeding in childbirth in 2 patients with type 3 von Willebrand disease. In one patient, the use of coagulation factor VIII with von Willebrand factor during in vitro fertilization was also shown.